Affinity DataIC50: 1.90nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 3.10nMAssay Description:Inhibition of recombinant GST-tagged human JAK1 (852 to 1142 residues) using IRS-1 as substrate in presence of 40 uM ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.60nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4.10nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:Inhibition of recombinant GST-tagged human JAK2 (809 to 1153 residues) catalytic cytoplasmic domain expressed in baculovirus expression system using ...More data for this Ligand-Target Pair
Affinity DataIC50: 5.80nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 8.5nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 9.5nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 9.90nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 24.7nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 29.3nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 40.4nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 52nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 53nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 53nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 57nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 58.6nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 62nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 66nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 89nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of recombinant human TYK2 (875-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Kinases used were human-derived JAK1, JAK2, JAK3, and TYK2 (Millipore, Germany). Each of these kinases was diluted with a suitable buffer solution as...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:Inhibition of recombinant human JAK2 (808-end residues) in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Inhibition of recombinant human JAK1 (866-end residues) in presence of ATPMore data for this Ligand-Target Pair